Trimel Pharmaceuticals Corporation (T.TRL) hit a new 52-week high of $4.71 Monday. Trimel announced today that the Company's ongoing CompleoTRT(TM) Phase III study has reached a key milestone in patient recruitment, with over 200 of the required study cohort of 280 patients now participating in the study.
The Company has benefited from recently expanding the number of active clinical sites from 30 to 37 in order to accelerate patient inflow and build study momentum towards an expected completion in the fourth quarter of 2012. The Phase III study represents the final stage of product development prior submission of a New Drug Application to the United States Food and Drug Administration for marketing approval.
Bauer Performance Sports Ltd. (T.BAU) hit a new 52-week high of $8.40 Monday. No news announcements today
SXC Health Solutions Corp. (T.SXC) hit a new 52-week high of $79.76 Monday. No news announcements today
Astral Media Inc. (T.ACM.A) hit a new 52-week high of $48.70 Monday. No news announcements today
Exco Technologies Limited (T.XTC) hit a new 52-week high of $5.00 Monday. No news announcements today
CML HealthCare Inc. (T.CLC) hit a new 52-week high of $10.95 Monday. No news announcements today
Alaris Royalty Corp. (T.AD) hit a new 52-week high of $19.18 Monday. No news announcements today
Related Stories
